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Double mutant P96S/S120G of Nm23-H1 abrogates its NDPK 
activity and motility-suppressive ability*
Zhou, Qinghua1 Yang, Xueqin2 Zhu, Daxing3 Ma, Li3 Zhu, Wen4 
1 Tianjin Lung Cancer Institute,Tianjin Medical University General 
Hospital, Tianjin, China 2 Cancer Center, West China Hospital, Sichuan 
University, Chengdu, China 3 Tianjin Lung Cancer Center, Tianjin 
Medical Unversity General Hospital, Tianjin, China 4 Key Lab. of Lung 
Cancer Molecular Biology of Sichuan Province,West China Hospital, 
Sichuan University, Chengdu, China 
Background: The Nm23-H1 gene is a metastasis suppressor gene. 
However, its biochemical mechanism of suppressing the met static 
potential of cancer cells is still unknown. The previous hypothesis that 
a histidine protein kinase activity may contributes to the motility-sup-
pressive effect of Nm23-H1 could not explain why the H118F mutant, 
a kinase-deﬁcient mutant, still had motility-suppressive ability. 
Methods: We conducted a study on the double mutant P96S/S120G 
of Nm223-H1 and succeeded in introducing the RP-HPLC method in 
NDPK assay. 
Results: The results showed that double mutant P96S/S120G, when 
expressed in the bacteria, was completely aggregated in inclusion 
bodies; prompted that the deﬁciency of motility-suppressive fuction of 
S120G, P96S, and P96S/S120G mutants was due to their altered struc-
ture, which might deprive Nm23-H1 of most activities including kinase 
activity or interactions with other proteins.
Conculsions: Double mutant P96S/S120G of Nm23-H1 abrogates its 
NDPK activity and motility-suppressive ability in the human high-
metastatic large cell lung cancer cell line L9981.
*This work was partly supported by the grants from the Key Proj-
ect of National Natural Science Foundation of China (to Qinghua 
Zhou)(No. 30430300), National Natural Science Foundation of China 
(to Qinghua Zhou) (No. 30070333), and the Research Found for the 
Doctoral Program of Higher Education of China (to Qinghua Zhou) 
(No. 20040610060) .
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Novel mechanism of collagen-tumor cell interaction by integrin 
alpha-11 expression by cancer associated fibroblasts in non-small 
cell lung cancer cells
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Background: The integrin α11 subunit is commonly overexpressed 
in non-small cell lung carcinoma (NSCLC). α11β1 integrin is a one of 
the four receptors for interstitial collagen. Immunoﬂuorescence study 
localized the protein mainly to the tumor stroma. α11 is also commonly 
overexpressed in cancer-associated ﬁbroblasts. We hypothesized that 
stromal expression of α11 may play important role in regulating the 
tumor formation of NSCLC cells. 
Methods: SV40 immortalized mouse embryonic ﬁbroblasts established 
from the wild type (WT) and α11 deﬁcient (KO) mice were tested for 
their tumorigenicity in immune deﬁcient mice when co-implanted with 
the A549 human lung adenocarcinoma cells. Fibroblasts and A549 
alone served as controls. Total cellular RNA was isolated from tumors 
formed and proﬁled using the Affymetrix U133A microarray, and 
differentially expressed genes were identiﬁed. Stable gene expression 
downregulation was accomplished by retroviral mediated transduction 
of short hairpin (sh) RNA. 
Results: A549 co-implanted with the ﬁbroblasts showed markedly 
increased tumor growth rate as compared with all control cell lines 
alone, which formed only small tumors. Importantly, the growth was 
signiﬁcantly greater for A549+WT compared to A549+KO tumors. The 
reduced tumorigenicity was also rescued by re-expression of human 
α11 in KO ﬁbroblasts. The tumor-promoting effect of ﬁbroblast α11 
was reproduced in 2 other NSCLC cell lines: NCI-H460 and -H520. 
Gene expression proﬁling indicated that IGF2 mRNA expression level 
was tightly regulated by alpha-11 in the ﬁbroblasts, and A549+KO tu-
mors expressed >200-fold lower IGF2 compared to A549+WT tumors. 
The shRNA downregulation of IGF2 in WT (WTsh-IGF2) ﬁbroblasts 
resulted in decreased growth rate of A549+WTsh-IGF2 compared to 
A549+WT tumors. In the orthotopic NCI-H460 human lung cancer 
model, host stromal α11 expression was signiﬁcantly higher in meta-
static compared to the primary tumors. 
Conclusion: Integrin α11 expressed on tumor stromal ﬁbroblasts 
provide a novel and alternate mechanism for collagen to modulate the 
growth of NSCLC cells, and IGF2 is one of the mediators for such 
activity. 
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Reverse transcriptase polymerase chain reaction assay designed 
for the detection of LUNX-mRNA to compare the micrometastasis 
during chemotherapy in patients with non-small cell lung cancer
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Objective: To compare the micrometastasis during chemotherapy in 
patients with non-small cell lung cancer. 
Material and Methods: To detect the expression of the lung tissue 
speciﬁc gene named LUNX with reverse transcriptase chain reaction 
method (RT-PCR) in peripheral blood of patients with non-small cell 
lung cancer (NSCLC), the micrometastasis of non-small cell lung 
cancer was diagnosed. 
Result: Total 20 patients was involved in the study, the peripheral 
blood was sampled before and after two cycles chemotherapy. There 
were 7 patients with NSCLC showed LUNX gene expression in blood 
before chemotherapy by RT-PCR.After two cycles of chemotherapy, 
there were 2 patients who was positive in blood detection. The positive 
detection rate of in peripheral blood in the group of before chemother-
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apy was evidently higher than the group of after two cycle chemo-
therapy. Nevertheless,there was no statistically signiﬁcant difference 
between two groups(P=0.063).
Conclusion: Effective chemotherapy may decrease the chance of 
micrometastasis.But it need to further proved.
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Background: Cisplatin is the most widely used agent in the chemo-
therapy of non-small cell lung cancer. In tumor cells, excision repair 
cross complement 1 (ERCC1) blocks the effect of cisplatin by repairing 
the cisplatin-DNA adduct, so the expression of ERCC1 in the tumor 
cells could be a predictor of response to chemotherapy. But the signiﬁ-
cance of the expression in the normal lung tissue is not well known. 
In this study, the levels of ERCC1 expression in the tumor tissue and 
normal tissue were compared.
Materials and Methods: The level of ERCC1 was measured in the 
tumor tissue from the surgical specimens of 28 patients with non-small 
cell lung cancer, using the real-time RT-PCR. In 13 patients, the expres-
sion of ERCC1 was measured in both the normal and the tumor tissues 
simultaneously. The ERCC1 levels of normal tissues and tumor tissues 
were also analysed according to the patients’ characteristics. The level 
was expressed as a percentage value compared to that of the A549 lung 
cancer cell line. 
Result: The mean level of ERCC1 expressions in 28 tumor tissues was 
signiﬁcantly higher than that in the normal tissues (192.9 % (0 - 1460.1 
%) vs. 8.2 % (0 to 28.2 %)). In the 13 cases, in which ERCC1 was mea-
sured simultaneously, ERCC1 was more increased in the tumor tissues 
except in two cases, but the differences were not signiﬁcant(p=0.233). 
When the upper limit of ERCC1 expression in the normal tissues (30 
%) was used as the cut-off level, 13 cases (46 %) expressed more than 
30 %. The differences of ERCC1 expression in the tumor tissues by the 
age, sex, smoking, CEA level, pathologic stages, T stages, N stages and 
cell types were not signiﬁcant. But some tendency of increased expres-
sion of ERCC1 was observed in the groups with higher T stages and 
adenocarcinoma histology. 
Conclusion: The expression of ERCC1 was higher in the tumor tissue 
than the normal tissue. However, the difference was insigniﬁcant. In 46 
% of the tumor tissues, ERCC1 was expressed above the highest level 
of the normal tissues. 
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Background: Tumor markers have not been generally recommended 
as a tool for the detection of lung cancer, because of the low speciﬁcity 
and sensitivity. Several reports have suggested the use of a combination 
of tumor markers in the follow-up of lung cancer patients, although 
the most useful combination remains subject to discussion. Here, using 
stepwise logistic regression analysis, the most useful combination with 
multiple serum tumor markers was examined for a prediction model in 
non-small cell lung cancer diagnosis.
Methods: We retrospectively reviewed our medical records of patients 
who had pre-operative measurements for seven serum tumor markers; 
carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-
9), cytokeratin 19-fragments (CYFRA 21-1), sialyl Lewis X-i antigen 
(SLX), Squamous cell carcinoma antigen (SCC), neuron speciﬁc 
enolase (NSE), pro-gastrin-releasing peptide (ProGRP). We conducted 
90 patients with non-small cell lung cancers and 10 with non-cancers 
who performed surgery for diagnosis or treatment in our department at 
Kansai Medical University Hospital from March 2004 to April 2005. 
Upper cutoff levels routinely used in our institution for CEA, CA19-9, 
CYFRA 21-1, SLX, SCC, NSE, ProGRP were 5 ng/ml, 37 ng/ml, and 
3.5 ng/ml, 38 ng/ml, 1.5 ng/ml, 10 ng/ml, 46 ng/ml, respectively. The 
prediction power for the diagnosis of lung cancer was evaluated by uni-
variate logistic regression analysis to calculate odds ratios, 95 percent 
conﬁdence intervals and area under receiver-operating characteristics 
(ROC) curves, using JMP version 5.1. Stepwise analysis was then used 
to select and identify the most important independent predictors of lung 
cancer. To strengthen the prediction model with the serum tumor mark-
ers selected by the stepwise analysis, we additionally collected data 
for 50 patients with lung cancers and 8 patients who were suspected to 
have lung cancers, but then appeared to have non-cancer nodules by 
pathological ﬁndings with surgical biopsies. The selected serum tumor 
markers, with totally 140 patients with lung cancers and 18 patients 
with non-cancer nodules, revised the prediction model for lung cancer 
diagnosis.
Results: Two of seven tumor markers; CEA, CYFRA 21-1, had statisti-
cal signiﬁcance in univariate analysis for prediction of lung cancer 
diagnosis (P-value; 0.0068 and 0.0012, respectively). The odds ratios 
were both signiﬁcantly high. Area under ROC curve were 0.79 and 
0.87, respectively. A stepwise logistic regression for lung cancer diag-
nosis using the seven serum tumor markers demonstrated that a model 
containing CEA and CYFRA 21-1 was the most predictive (P<0.0001, 
area under ROC curve; 0.91). Revised prediction model using CEA and 
CYFRA 21-1 with total 158 cases including additional 50 lung cancers 
and 8 non-cancer nodules showed statistical signiﬁcance (area under 
ROC curve; 0.85). Using the revised model with CEA and CYFRA 
21-1, a cut-off value for lung cancer diagnosis showed that sensitivity 
was 0.7 and speciﬁcity was 0.94, although 47 % of CEA and 74 % of 
CYFRA 21-1 were negative.
Conclusions: Prediction model with multiple serum tumor markers is 
potentially useful for lung cancer diagnosis. CEA and CYFRA 21-1 
were the candidates to develop the prediction model in non-small cell 
lung cancer.
